Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Resproly logo — Pioneering advanced respiratory solutions for Asthma, COPD,...

Resproly

Pioneering advanced respiratory solutions for Asthma, COPD, Diabetes, and Parkinson's Disease.

Founded 2018 Series B Total: $81.00M Biopharma, Biotechnology +1

General Information

Company Name Resproly
Founded Year 2018
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Resproly. To contact Resproly, visit resproly.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Resproly

Resproly is an integrated enterprise dedicated to pioneering advanced respiratory solutions, focusing on specific treatment areas such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Diabetes, and Parkinson's Disease. Established in 2018, the company operates within the Biopharma, Biotechnology, and Health Care industries.

The most recent funding round took place on 30 April 2022, with a Series B investment from prominent investors including Qianhai Fund of Funds, Fuho Capital, and BioVenture.

Taxonomy: respiratory solutions, inhalation formulas, medical equipment, clinical treatment, respiratory diseases, Asthma, COPD, Diabetes, Parkinson's Disease, pharmaceuticals, innovation, integrated enterprise, healthcare devices

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B Undisclosed 3
Qianhai Fund of Funds Fuho Capital
Qianhai Fund of Funds, Fuho Capital +1
30 Apr 2022
Series B $31.00M 1
CAS Investment Management
CAS Investment Management
03 Feb 2021
Series A CNY50.00M 3
Huaige Capital Zhuhai Gree Financial Investment Management
Huaige Capital, Zhuhai Gree Financial Investment Management +1
29 Aug 2019

Resproly Alternatives & Competitors

View All Alternatives
Resproly vs
OMNI
OMNI

Pioneering advanced respiratory drug delivery solutions for asthma and chronic obstructive pulmonary...

Series D
Biotechnology, Health Care
Resproly vs
Trimel Pharmaceuticals
Trimel Pharmaceuticals

Pioneering innovative solutions for male hypogonadism, female sexual dysfunction, and respiratory di...

Post-IPO Equity
Biotechnology, Health Care
Resproly vs
Chance Pharmaceuticals 畅溪制药
Chance Pharmaceuticals 畅溪制药 China

A clinical-stage biotech company focusing on discovering, developing and commercializing inhalation...

Series C
3 employees
Biotechnology, Health Care
View all alternatives

FAQ About Resproly

Pioneering advanced respiratory solutions for Asthma, COPD, Diabetes, and Parkinson's Disease.
Resproly was founded in 2018.
Resproly operates in Biopharma, Biotechnology and Health Care. Its work centres on respiratory solutions, inhalation formulas, medical equipment and clinical treatment.
Resproly has completed 3 funding rounds, raising a total of $81.00M. The latest funding stage is Series B.
Top alternatives and competitors to Resproly include OMNI, Trimel Pharmaceuticals, Chance Pharmaceuticals 畅溪制药, ProteoTech, Activaero GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Resproly and OMNI are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Resproly, https://bouncewatch.com/company/resproly, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes